Literature DB >> 68993

Induction of immunological tolerance requires that the B cells can respond to the polyclonal B-cell-activating properties of the thymus-independent antigens.

C Fernandez, G Möller.   

Abstract

Mice were rendered specifically tolerant to the fluorescein isothiocyanatedextran (FITC) epitope by injection of FITC-dextran B512. Their spleen cells were removed at various times and cultivated in vitro with different polyclonal B-cell activators, such as lipopolysaccharide (LPS), purified protein derivative of tuberculin, and native dextran. LPS caused the appearance of high affinity anti-FITC plaque-forming cells to an equal extent with cells from untreated and tolerant animals, whereas native dextran failed to activate cells from tolerant mice, although it was a potent activator of normal cells. It was concluded that tolerance induction only affects those B cells that could respond to the polyclonal B-cell-activating properties of the tolerogen, but not other B cells having an identical set of Ig receptors directed against the tolerogen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 68993      PMCID: PMC2180727          DOI: 10.1084/jem.146.1.308

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

Review 1.  Thymus-independent B-cell induction and paralysis.

Authors:  A Coutinho; G Möller
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

2.  Lack of effect of thymectomy on spontaneous recovery from tolerance to levan.

Authors:  J G Howard; B M Courtenay; C Hale
Journal:  Eur J Immunol       Date:  1976-11       Impact factor: 5.532

3.  Plaque formation in agar by single antibody-producing cells.

Authors:  N K JERNE; A A NORDIN
Journal:  Science       Date:  1963-04-26       Impact factor: 47.728

Review 4.  Immunological tolerance.

Authors:  J G Howard; N A Mitchison
Journal:  Prog Allergy       Date:  1975

5.  Spleen cells from animals tolerant to a thymus-dependent antigen can be activated by lipopolysaccharide to synthesize antibodies against the tolerogen.

Authors:  G Möller; E Gronowicz; U Persson; A Coutinho; E Möller; L Hammarström; E Smith
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

6.  A theory of self-nonself discrimination.

Authors:  P Bretscher; M Cohn
Journal:  Science       Date:  1970-09-11       Impact factor: 47.728

7.  Rapid breaking of tolerance against Escherichia coli lipopolysaccharide in vivo and in vitro.

Authors:  O Sjöberg
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

  7 in total
  6 in total

Review 1.  Current perspectives on the cellular mechanisms of immunologic tolerance.

Authors:  D E Parks; W O Weigle
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

2.  Antigen-induced strain-specific autoantiidiotypic antibodies modulate the immune response to dextran B 512.

Authors:  C Fernandez; G Möller
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

3.  Contrasting effects of H-2 and Mls immunization on the polyclonal mitogenicity of murine lymphocytes.

Authors:  A Matossian-Rogers
Journal:  Immunology       Date:  1979-08       Impact factor: 7.397

4.  Initiation of assembly and association of the structural elements of a bacterial pilus depend on two specialized tip proteins.

Authors:  F Jacob-Dubuisson; J Heuser; K Dodson; S Normark; S Hultgren
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

5.  Immunological unresponsiveness to thymus-independent antigens: two fundamentally different genetic mechanisms of B-cell unresponsiveness to dextran.

Authors:  C Fernandez; G Möller
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

6.  Induction and mode of action of suppressor cells generated against human gamma globulin. I. An immunologic unresponsive state devoid of demonstrable suppressor cells.

Authors:  D E Parks; M V Doyle; W O Weigle
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.